This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Jun;78(6):681-3.

doi: 10.4065/78.6.681.

Advances in medical management of overactive bladder

Elliott Richelson, Daniel S Elliott

PMID: 12934775
DOI: 10.4065/78.6.681

Editorial

Advances in medical management of overactive bladder

Elliott Richelson et al. Mayo Clin Proc. 2003 Jun.

. 2003 Jun;78(6):681-3.

doi: 10.4065/78.6.681.

Authors

Elliott Richelson, Daniel S Elliott

PMID: 12934775
DOI: 10.4065/78.6.681

No abstract available

PubMed Disclaimer

Comment on

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH; OPERA Study Group. Diokno AC, et al. Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687. Mayo Clin Proc. 2003. PMID: 12934777 Clinical Trial.
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Appell RA, et al. Mayo Clin Proc. 2003 Jun;78(6):696-702. doi: 10.4065/78.6.696. Mayo Clin Proc. 2003. PMID: 12934778 Clinical Trial.

Similar articles

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH; OPERA Study Group. Diokno AC, et al. Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687. Mayo Clin Proc. 2003. PMID: 12934777 Clinical Trial.
Detrol LA and Diropan XL for overactive bladder.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2001 Apr 2;43(1101):28. Med Lett Drugs Ther. 2001. PMID: 11283473 No abstract available.
The newer antimuscarinic drugs: bladder control with less dry mouth.
Appell RA. Appell RA. Cleve Clin J Med. 2002 Oct;69(10):761, 765-6, 768-9. doi: 10.3949/ccjm.69.10.761. Cleve Clin J Med. 2002. PMID: 12371799 Review.
Oxybutynin transdermal (Oxytrol) for overactive bladder.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2003 May 12;45(1156):38-9. Med Lett Drugs Ther. 2003. PMID: 12736598 No abstract available.
Tolterodine.
Hills CJ, Winter SA, Balfour JA. Hills CJ, et al. Drugs. 1998 Jun;55(6):813-20; discussion 821-2. doi: 10.2165/00003495-199855060-00008. Drugs. 1998. PMID: 9617596 Review.

See all similar articles

Cited by

Extending the rationale of combination therapy to unresponsive erectile dysfunction.
Reece C, Kumar R, Nienow D, Nehra A. Reece C, et al. Rev Urol. 2007 Fall;9(4):197-206. Rev Urol. 2007. PMID: 18231616 Free PMC article.
Management of overactive bladder with transdermal oxybutynin.
Starkman JS, Dmochowski RR. Starkman JS, et al. Rev Urol. 2006 Summer;8(3):93-103. Rev Urol. 2006. PMID: 17043706 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information